Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2+ pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice.
Yaya ChuGaurav NayyarSusiyan JiangJeremy M RosenblumPatrick Soon-ShiongJeffrey T SafritDean A LeeMitchell S CairoPublished in: Journal for immunotherapy of cancer (2022)
Our results provide the rationale for the development of a clinical trial of N-803 in combination with dinutuximab and ex vivo exPBNK cells in patients with recurrent or metastatic GD2+ solid tumors.